Joint press release : Boiron and Lehning laboratories have filed two appeals against the decrees of August,30 2019 concerning the phasing out of reimbursement of homoeopathic drugs and remedies by 2021
October 23, 2019 at 10:45 am EDT
Share
PRESS RELEASE
Paris, October 23, 2019
Boiron and Lehning laboratories have filed two appeals against the decrees of
August,30 2019 concerning the phasing out of reimbursement of
homoeopathic drugs and remedies by 2021.
******
Boiron and Lehning laboratories wish to announce that they have asked the Conseil d'Etat (France's highest administrative court) to quash the following orders:
Decree no. 2019-905 which temporarily reduces the amount covered by the health insurance fund for homoeopathic drugs and preparations from 30 to 15%
Decree no. 2019-904 which excludes homoeopathic preparations from being covered by the health insurance fund, starting on a date fixed by decree and no later than 1st January 2021.
These appeals focus on both the irregularities which have tainted the homoeopathy assessment procedure conducted by the French Health Authority transparency commission, and the ill-founded nature of these decrees.
An application for a priority preliminary ruling on the issue of constitutionality (QPC) will also be presented in order to challenge the law, which delegated the decision concerning coverage of homoeopathic medicines to a single minister.
Filing these appeals triggers the start of a procedure which could last between 12 and 18 months. The laboratories will not comment on changes to the dossier before the Conseil d'Etat announces its decision.
Filing these appeals is also a statement of how confident these laboratories are as to the efficacy of homoeopathy and its validity and relevance to public health, as well as their desire to ensure access for all to this type of therapy.
Press contact: DGM - Thomas de Climens - thomasdeclimens@dgm-conseil.fr- 0614501584
Boiron SA published this content on 23 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 October 2019 14:44:04 UTC
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues.
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (47.9%), Europe (24.7%), North America (24.4%) and other (3%).
Joint press release : Boiron and Lehning laboratories have filed two appeals against the decrees of August,30 2019 concerning the phasing out of reimbursement of homoeopathic drugs and remedies by 2021